Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03905148
Title Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BeiGene
Indications

Advanced Solid Tumor

endometrial cancer

lung non-small cell carcinoma

Therapies

BGB-283 + PD-0325901

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.